Search company, investor...

Founded Year



Unattributed VC | Alive

Total Raised


Last Raised

$5M | 18 yrs ago

About Optobionics

Optobionics focuses on artificial vision technology within the medical devices sector. The company's main offering is the Artificial Silicon Retina (ASR) implants designed to restore vision for patients with certain eye conditions. These implants are aimed at individuals suffering from vision loss due to retinal diseases. It was founded in 1990 and is based in Glen Ellyn, Illinois.

Headquarters Location

386 Pennsylvania Avenue Suite 3N

Glen Ellyn, Illinois, 60137,

United States




Latest Optobionics News

Innovative Solutions for Vision Restoration: Artificial Retina Market Expands to 2031 - Players Include LambdaVision, Nano Retina, Nidek and Optobionics

Sep 11, 2023

Dublin, Sept. 11, 2023 (GLOBE NEWSWIRE) -- The "Artificial Retina Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts - 2023 to 2031" report has been added to's offering.

Optobionics Frequently Asked Questions (FAQ)

  • When was Optobionics founded?

    Optobionics was founded in 1990.

  • Where is Optobionics's headquarters?

    Optobionics's headquarters is located at 386 Pennsylvania Avenue, Glen Ellyn.

  • What is Optobionics's latest funding round?

    Optobionics's latest funding round is Unattributed VC.

  • How much did Optobionics raise?

    Optobionics raised a total of $35.65M.

  • Who are the investors of Optobionics?

    Investors of Optobionics include Polaris Partners, Advanced Technology Ventures, ARCH Venture Partners, Medtronic, Abbott Medical Optics and 4 more.



CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.